Measles virus offers an ideal platform from which to build a new generation of safe, effective
oncolytic viruses. Occasional so-called spontaneous tumor regressions have occurred …

Oncolytic virotherapeutic agents are likely to become serious contenders in cancer
treatment. The vaccine strain of measles virus is an agent with an impressive range of …

The hemagglutinin (H) protein of measles virus (MeV) interacts with a cellular receptor which
constitutes the initial stage of infection. Binding of H to this host cell receptor subsequently …

The use of replicating viruses for cancer therapy is attracting increasing interest. Numerous
viruses are now being considered as potential cancer therapeutics, including the vaccine …

Simple Summary Measles virus is currently under investigation as an innovative cancer
treatment. The virus selectively replicates in and kills cancer cells. Furthermore, it can be …

Viral vector systems are widely being used in the development of new genetic approaches
for a variety of human diseases. Oncolytic viruses have shown great potential as cancer …

Introduction: Replication-competent oncolytic measles virus (MV) strains preferentially infect
and destroy a wide variety of cancer tissues. Clinical translation of engineered attenuated …

Oncolytic viruses hold much promise as novel therapeutic agents that can be combined with
conventional therapeutic modalities. Measles virus (MV) is known to enter cells using the …

Introduction: Oncolytic viruses represent a novel treatment modality that is unencumbered by
the standard resistance mechanisms limiting the therapeutic efficacy of conventional …

Measles virus (MV) is a negative‐strand RNA virus (paramyxovirus) with oncolytic
properties. The significant preclinical activity of MV vaccine strains against a variety of tumor …